Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Seroprevalence of anti-SARS-CoV-2 antibodies in COVID-19 patients and healthy volunteers

View ORCID ProfilePatrícia Figueiredo-Campos, View ORCID ProfileBirte Blankenhaus, View ORCID ProfileCatarina Mota, Andreia Gomes, Marta Serrano, View ORCID ProfileSilvia Ariotti, View ORCID ProfileCatarina Costa, View ORCID ProfileHelena Nunes-Cabaço, View ORCID ProfileAntónio M. Mendes, View ORCID ProfilePedro Gaspar, View ORCID ProfileM. Conceição Pereira-Santos, Fabiana Rodrigues, Jorge Condeço, M. Antonia Escoval, Matilde Santos, View ORCID ProfileMario Ramirez, View ORCID ProfileJosé Melo-Cristino, View ORCID ProfileJ. Pedro Simas, Eugenia Vasconcelos, Ângela Afonso, View ORCID ProfileMarc Veldhoen
doi: https://doi.org/10.1101/2020.08.30.20184309
Patrícia Figueiredo-Campos
1Instituto de Medicina Molecular | João Lobo Antunes, Faculdade de Medicina da Universidade de Lisboa, Av. Professor Egas Moniz, Lisbon, 1649-028, Portugal
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Patrícia Figueiredo-Campos
Birte Blankenhaus
1Instituto de Medicina Molecular | João Lobo Antunes, Faculdade de Medicina da Universidade de Lisboa, Av. Professor Egas Moniz, Lisbon, 1649-028, Portugal
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Birte Blankenhaus
Catarina Mota
1Instituto de Medicina Molecular | João Lobo Antunes, Faculdade de Medicina da Universidade de Lisboa, Av. Professor Egas Moniz, Lisbon, 1649-028, Portugal
2Centro Hospitalar Universitário Lisboa Norte, EPE, Av. Professor Egas Moniz, Lisbon, 1649-028, Portugal
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Catarina Mota
Andreia Gomes
1Instituto de Medicina Molecular | João Lobo Antunes, Faculdade de Medicina da Universidade de Lisboa, Av. Professor Egas Moniz, Lisbon, 1649-028, Portugal
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marta Serrano
1Instituto de Medicina Molecular | João Lobo Antunes, Faculdade de Medicina da Universidade de Lisboa, Av. Professor Egas Moniz, Lisbon, 1649-028, Portugal
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Silvia Ariotti
1Instituto de Medicina Molecular | João Lobo Antunes, Faculdade de Medicina da Universidade de Lisboa, Av. Professor Egas Moniz, Lisbon, 1649-028, Portugal
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Silvia Ariotti
Catarina Costa
1Instituto de Medicina Molecular | João Lobo Antunes, Faculdade de Medicina da Universidade de Lisboa, Av. Professor Egas Moniz, Lisbon, 1649-028, Portugal
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Catarina Costa
Helena Nunes-Cabaço
1Instituto de Medicina Molecular | João Lobo Antunes, Faculdade de Medicina da Universidade de Lisboa, Av. Professor Egas Moniz, Lisbon, 1649-028, Portugal
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Helena Nunes-Cabaço
António M. Mendes
1Instituto de Medicina Molecular | João Lobo Antunes, Faculdade de Medicina da Universidade de Lisboa, Av. Professor Egas Moniz, Lisbon, 1649-028, Portugal
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for António M. Mendes
Pedro Gaspar
2Centro Hospitalar Universitário Lisboa Norte, EPE, Av. Professor Egas Moniz, Lisbon, 1649-028, Portugal
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Pedro Gaspar
M. Conceição Pereira-Santos
1Instituto de Medicina Molecular | João Lobo Antunes, Faculdade de Medicina da Universidade de Lisboa, Av. Professor Egas Moniz, Lisbon, 1649-028, Portugal
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for M. Conceição Pereira-Santos
Fabiana Rodrigues
1Instituto de Medicina Molecular | João Lobo Antunes, Faculdade de Medicina da Universidade de Lisboa, Av. Professor Egas Moniz, Lisbon, 1649-028, Portugal
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jorge Condeço
3Instituto Português do Sangue e Transplantação (IPST), Av. do Brasil 53 - Pav. 17, Lisbon, 1749-005, Portugal
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
M. Antonia Escoval
3Instituto Português do Sangue e Transplantação (IPST), Av. do Brasil 53 - Pav. 17, Lisbon, 1749-005, Portugal
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Matilde Santos
3Instituto Português do Sangue e Transplantação (IPST), Av. do Brasil 53 - Pav. 17, Lisbon, 1749-005, Portugal
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mario Ramirez
1Instituto de Medicina Molecular | João Lobo Antunes, Faculdade de Medicina da Universidade de Lisboa, Av. Professor Egas Moniz, Lisbon, 1649-028, Portugal
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Mario Ramirez
José Melo-Cristino
1Instituto de Medicina Molecular | João Lobo Antunes, Faculdade de Medicina da Universidade de Lisboa, Av. Professor Egas Moniz, Lisbon, 1649-028, Portugal
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for José Melo-Cristino
J. Pedro Simas
1Instituto de Medicina Molecular | João Lobo Antunes, Faculdade de Medicina da Universidade de Lisboa, Av. Professor Egas Moniz, Lisbon, 1649-028, Portugal
4instituto de Ciências de Saúde, Universidade Católica Portuguesa, Palma de Cima 1649-028, Lisboa
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for J. Pedro Simas
Eugenia Vasconcelos
3Instituto Português do Sangue e Transplantação (IPST), Av. do Brasil 53 - Pav. 17, Lisbon, 1749-005, Portugal
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ângela Afonso
1Instituto de Medicina Molecular | João Lobo Antunes, Faculdade de Medicina da Universidade de Lisboa, Av. Professor Egas Moniz, Lisbon, 1649-028, Portugal
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marc Veldhoen
1Instituto de Medicina Molecular | João Lobo Antunes, Faculdade de Medicina da Universidade de Lisboa, Av. Professor Egas Moniz, Lisbon, 1649-028, Portugal
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Marc Veldhoen
  • For correspondence: marc.veldhoen@medicina.ulsboa.pt
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

SARS-CoV-2 has emerged as a novel human pathogen, causing clinical signs, from fever to pneumonia – COVID-19 – but may remain mild or even asymptomatic. To understand the continuing spread of the virus, to detect those who are and were infected, and to follow the immune response longitudinally, reliable and robust assays for SARS-CoV-2 detection and immunological monitoring are needed and have been setup around the world. We quantified immunoglobulin M (IgM), IgG and IgA antibodies recognizing the SARS-CoV-2 receptor-binding domain (RBD) or the Spike (S) protein over a period of five months following COVID-19 disease onset or in previously SARS-CoV-2 PCR-positive volunteers. We report the detailed setup to monitor the humoral immune response from over 300 COVID-19 hospital patients and healthcare workers, 2500 University staff and 187 post-COVID19 volunteers, and assessing titres for IgM, IgG and IgA. Anti-SARS-CoV-2 antibody responses followed a classic pattern with a rapid increase within the first three weeks after symptoms. Although titres reduce from approximately four weeks, the ability to detect SARS-CoV-2 antibodies remained robust for five months in a large proportion of previously virus-positive screened subjects. Our work provides detailed information for the assays used, facilitating further and longitudinal analysis of protective immunity to SARS-CoV-2. Moreover, it highlights a continued level of circulating neutralising antibodies in most people with confirmed SARS-CoV-2, at least up to five months after infection.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

We like to acknowledge the funding from the European Union H2020 ERA project (No 667824 - EXCELLtoINNOV) and the Fundacao para a Ciencia e a Tecnologia (FCT) to P.F-C. (SFRH/BD/131605/2017), PTDC/MED-IMU/28003/2017, and research4COVID19 (no 231_596873172, Generating SARS-CoV2 seroconversion assay and no 729, High-throughput SARS-CoV2 neutralising antibodies assessment), with additional support by Sociedade Francisco Manuel dos Santos.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Serum samples were obtained from the iMM biobank COVID-19 collection, and pre-pandemic control sera from two allergy collections. Patients were recruited from the COVID-19 unit and the Allergy Department of Hospital de Santa Maria, Centro Hospitalar Lisboa Norte. The COVID-19 collection and scientific use was approved by the Lisbon Academic Medical Center Ethics Committee (Ref. no 155/20) as was the staff screening (Ref. no 181/20). The allergy studies were approved with reference 116/13. Potential plasma donors registered voluntarily via the IPST website. Criteria for registration were a diagnosis of COVID-19 documented by a positive PCR test for SARS-CoV2 followed by two negative or one negative PCR tests 14 or 28 days prior to collection, respectively. Medical interviews were conducted to ensure that the criteria for apheresis plasma donation were fulfilled and that a fully recovery from COVID-19 had been achieved. Signed informed consent was obtained from all volunteers. All data were treated confidentially and anonymous, according to (EU) 2016/679 of 27 April 2016 (General Data Protection Regulation). A professional obliged to confidentiality with guarantee appropriate information security measures carried out the data collection under the terms of the GDPR paragraph 2, article 29 Law no. 58 /2019, 8th August.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

Supplementary methods and figures have been submitted. Any data will be made available upon reasonable request. This manuscript does not contain other large data sets, but for ELISA plate readouts.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.
Back to top
PreviousNext
Posted September 02, 2020.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Seroprevalence of anti-SARS-CoV-2 antibodies in COVID-19 patients and healthy volunteers
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Seroprevalence of anti-SARS-CoV-2 antibodies in COVID-19 patients and healthy volunteers
Patrícia Figueiredo-Campos, Birte Blankenhaus, Catarina Mota, Andreia Gomes, Marta Serrano, Silvia Ariotti, Catarina Costa, Helena Nunes-Cabaço, António M. Mendes, Pedro Gaspar, M. Conceição Pereira-Santos, Fabiana Rodrigues, Jorge Condeço, M. Antonia Escoval, Matilde Santos, Mario Ramirez, José Melo-Cristino, J. Pedro Simas, Eugenia Vasconcelos, Ângela Afonso, Marc Veldhoen
medRxiv 2020.08.30.20184309; doi: https://doi.org/10.1101/2020.08.30.20184309
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Seroprevalence of anti-SARS-CoV-2 antibodies in COVID-19 patients and healthy volunteers
Patrícia Figueiredo-Campos, Birte Blankenhaus, Catarina Mota, Andreia Gomes, Marta Serrano, Silvia Ariotti, Catarina Costa, Helena Nunes-Cabaço, António M. Mendes, Pedro Gaspar, M. Conceição Pereira-Santos, Fabiana Rodrigues, Jorge Condeço, M. Antonia Escoval, Matilde Santos, Mario Ramirez, José Melo-Cristino, J. Pedro Simas, Eugenia Vasconcelos, Ângela Afonso, Marc Veldhoen
medRxiv 2020.08.30.20184309; doi: https://doi.org/10.1101/2020.08.30.20184309

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (280)
  • Allergy and Immunology (577)
  • Anesthesia (139)
  • Cardiovascular Medicine (1942)
  • Dentistry and Oral Medicine (252)
  • Dermatology (183)
  • Emergency Medicine (331)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (697)
  • Epidemiology (11086)
  • Forensic Medicine (8)
  • Gastroenterology (619)
  • Genetic and Genomic Medicine (3156)
  • Geriatric Medicine (307)
  • Health Economics (560)
  • Health Informatics (2037)
  • Health Policy (861)
  • Health Systems and Quality Improvement (781)
  • Hematology (309)
  • HIV/AIDS (682)
  • Infectious Diseases (except HIV/AIDS) (12702)
  • Intensive Care and Critical Care Medicine (707)
  • Medical Education (317)
  • Medical Ethics (92)
  • Nephrology (334)
  • Neurology (2977)
  • Nursing (162)
  • Nutrition (461)
  • Obstetrics and Gynecology (589)
  • Occupational and Environmental Health (614)
  • Oncology (1548)
  • Ophthalmology (474)
  • Orthopedics (185)
  • Otolaryngology (265)
  • Pain Medicine (201)
  • Palliative Medicine (57)
  • Pathology (402)
  • Pediatrics (909)
  • Pharmacology and Therapeutics (381)
  • Primary Care Research (354)
  • Psychiatry and Clinical Psychology (2774)
  • Public and Global Health (5583)
  • Radiology and Imaging (1090)
  • Rehabilitation Medicine and Physical Therapy (630)
  • Respiratory Medicine (755)
  • Rheumatology (338)
  • Sexual and Reproductive Health (311)
  • Sports Medicine (287)
  • Surgery (342)
  • Toxicology (48)
  • Transplantation (159)
  • Urology (131)